All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Mutter Discusses Partial Breast Irradiation in Low-Risk Breast Cancer

March 15th 2024

Robert W. Mutter, MD, discusses the nuances of partial breast irradiation in early-stage breast cancer.

Post-Hoc Analysis Shows Dose-Escalated Radiation is Safe and Efficacious in Intrahepatic Cholangiocarcinoma

March 15th 2024

A post-hoc analysis showed dose escalation of radiation therapy was safe and elicited similar efficacy in intrahepatic cholangiocarcinoma.

Advanced Radiation Techniques Could Aid in Cardiac Sparing in Lung, Breast, and Esophageal Cancer Treatment

March 15th 2024

Charles B. Simone II, MD, FASTRO, FACRO, discusses advanced radiation techniques that could reduce cardiac toxicities.

FDA ODAC Committee Votes in Favor of Benefit-Risk Profile of Ide-Cel in Early R/R Myeloma

March 15th 2024

The FDA’s Oncologic Drugs Advisory Committee voted in favor of idecabtagene vicleucel for patients with early relapsed/refractory myeloma.

Deep Dive into a Case Study on Liver-Sparing TBI Plus Helical Tomotherapy in Relapsed Pre-B Cell ALL

March 15th 2024

A case study of a patient with pre-B cell acute lymphoblastic leukemia showed helical tomotherapy with IMRT-based TBI is a viable option for organ sparing.

Navigating Career Crossroads: Insights from Hope Rugo’s Journey as a Woman in Oncology

March 15th 2024

Hope S. Rugo, MD, draws on her own journey as a woman in oncology to provide insights on navigating career transitions and building support networks.

FDA ODAC Committee Votes Unanimously in Favor of Benefit-Risk Profile of Cilta-Cel in Early R/R Myeloma

March 15th 2024

The FDA’s Oncologic Drugs Advisory Committee voted in favor of ciltacabtagene autoleucel for patients with early relapsed/refractory myeloma.

Pembrolizumab Plus Concurrent CRT Meets OS End Point in High-Risk, Locally Advanced Cervical Cancer

March 15th 2024

The KEYNOTE-A18 trial met its coprimary end point of improved OS with pembrolizumab plus concurrent chemoradiotherapy in high-risk cervical cancer.

Potential New Treatment for Head and Neck Cancers

March 15th 2024

Some head and neck cancers may respond to the drug olaparib or the combination of olaparib with decitabine.

Graff Highlights the Importance of Perseverance and Self-Advocacy as a Woman in Oncology

March 15th 2024

Stephanie L. Graff, MD, shares her journey to becoming an oncologist, advice for work-life balance, and ways to confront gender bias in medicine.

FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory CLL or SLL

March 15th 2024

The FDA has granted accelerated approval to lisocabtagene maraleucel for the treatment of select patients with relapsed/refractory CLL or SLL.

QOL Remains a Key Goal of the Use of Radiation in Rectal Cancer

March 14th 2024

Nina Sanford, MD, discusses how radiation could help improve QOL for patients with rectal cancer and situations when radiation or surgery could be omitted.

Retrospective Study Shows Neoadjuvant SCRT is Associated With Optimal Surgical Outcomes in Rectal Cancer

March 14th 2024

Prolonged duration from neoadjuvant SCRT to surgery did not increase the risk of poor mesorectum specimen quality or post-operative morbidity in rectal cancer.

FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy

March 14th 2024

The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.

Brown Details the Evolving Role of PCI and HA-PCI in Small Cell Lung Cancer

March 14th 2024

Paul D. Brown, MD, gives a history of prophylactic cranial irradiation in small cell lung cancer and describes its standing in the treatment paradigm.

FDA ODAC Committee Votes In Favor of Benefit-Risk Profile of Imetelstat in Lower-Risk MDS

March 14th 2024

The FDA’s Oncologic Drugs Advisory Committee voted in favor of imetelstat for select patients with lower-risk myelodysplastic syndrome.

Japanese Approval Sought for Datopotamab Deruxtecan in Pretreated HR+/HER2– Advanced Breast Cancer

March 14th 2024

A new drug application seeking the approval of Dato-DXd for pretreated HR-positive, HER2-negative advanced breast cancer has been filed in Japan.

Phase 1 Trial of IMM-1-104 Generates Positive Topline Results in RAS-Mutant Solid Tumors

March 14th 2024

Initial antitumor activity and safety data have been observed in the phase 1 portion of a phase 1/2a trial of IMM-1-104 in RAS-mutant solid tumors.

FDA Grants Orphan Drug Designation to P-BCMA-ALLO1 in R/R Multiple Myeloma

March 14th 2024

P-BCMA-ALLO1 has been granted orphan drug designation by the FDA for the treatment of patients with relapsed/refractory multiple myeloma.

Study Reveals New Insights Into Immune System Role in Lung Cancer Risk

March 14th 2024

A study sheds light on how immune genetics influence lung cancer risk, potentially paving the way for enhanced prevention strategies and screening.